BUY Conviction2/5 Analysis quality55/100 now
Regeneron Pharmaceuticals, a large biotech, has seen a significant return over the past five years, leading to a high share price. While it has no history of splitting its stock, its steady revenue and profitability might convince the board to consider a split.
“also just over $1,000 a share here is regeneron Pharmaceuticals tier RN with no history of splitting its stock but a steady 272 return over the past 5 years that might convince the board that the shares have run too high on that price”